Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.
暂无分享,去创建一个
W. Gerald | W. Travis | W. Pao | J. Bromberg | W. Bornmann | D. Veach | B. Clarkson | S. Gao | K. Leslie | N. Motoi | Kevin G Mark
[1] W. Pao,et al. Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.
[2] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[3] W. Gerald,et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[4] J. S. Gutkind,et al. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. , 2003, Cancer research.
[5] G. Bepler,et al. Activated Epidermal Growth Factor Receptor–Stat-3 Signaling Promotes Tumor Survival In vivo in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[6] D. Coppola,et al. Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer. , 2006, Clinical lung cancer.
[7] Stefano Monti,et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[9] Helen H. W. Chen,et al. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion , 2006, Oncogene.
[10] E. Spangenburg,et al. Exercise increases SOCS‐3 expression in rat skeletal muscle: potential relationship to IL‐6 expression , 2006, The Journal of physiology.
[11] J. Marshall. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors , 2006, Cancer.
[12] B. Jenkins,et al. STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis. , 2006, Gastroenterology.
[13] H. Varmus,et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. , 2006, Genes & development.
[14] N. Liverton,et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. , 2002, Bioorganic & medicinal chemistry letters.
[15] J. Darnell,et al. Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.
[16] Heike Knüpfer,et al. Significance of interleukin-6 (IL-6) in breast cancer (review) , 2007, Breast Cancer Research and Treatment.
[17] J. Bromberg. Stat proteins and oncogenesis. , 2002, The Journal of clinical investigation.
[18] P. Sehgal,et al. Regulation of IL6 gene expression. , 1992, Research in immunology.
[19] D. Berry,et al. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806 , 2006, Breast Cancer Research and Treatment.
[20] J. S. Gutkind,et al. Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. , 2006, Neoplasia.
[21] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[22] L. Ivashkiv,et al. Role of STAT3 in Type I Interferon Responses , 2006, Journal of Biological Chemistry.
[23] D. Haber,et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. , 2006, Cancer cell.
[24] Matthew Meyerson,et al. Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255 , 2004, Cancer Research.
[25] S. Sone,et al. Serum levels of interleukin 6 in patients with lung cancer. , 1995, British Journal of Cancer.
[26] J. Russo,et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. , 1990, Cancer research.
[27] G. Stark,et al. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. , 2007, Genes & development.
[28] Huang Shao,et al. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. , 2003, Cancer research.
[29] T. Kishimoto. Interleukin-6: from basic science to medicine--40 years in immunology. , 2005, Annual review of immunology.
[30] M. Ladanyi,et al. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. , 2005, The Journal of molecular diagnostics : JMD.
[31] Jing Ma,et al. Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling. , 2003, The Biochemical journal.
[32] Daniel A. Haber,et al. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.
[33] Eric B Haura,et al. Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer , 2005, Nature Clinical Practice Oncology.
[34] W. Farrar,et al. Co‐operative functions between nuclear factors NFκB and CCAT/enhancer‐binding protein‐β (C/EBP‐β) regulate the IL‐6 promoter in autocrine human prostate cancer cells , 2004 .
[35] Roy Garcia,et al. STATs in oncogenesis , 2000, Oncogene.
[36] J. Turkson,et al. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells , 2003, Oncogene.
[37] Hua Yu,et al. The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.
[38] J. Bromberg,et al. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. , 2006, Cancer research.
[39] H. Kung,et al. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells , 1998, Nature.
[40] N. Usami,et al. STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT3. , 2004, International journal of oncology.
[41] H. Land,et al. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. , 1990, Nucleic acids research.
[42] L. Flowers,et al. A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells , 2005, Oncogene.
[43] C. Van Waes,et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF‐κB and AP‐1 activation and IL‐8 and VEGF expression in human head and neck squamous cell carcinoma lines , 2002, International journal of cancer.
[44] C. Begley,et al. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells , 2002, Oncogene.
[45] A. Yoshimura,et al. Suppression of IL-6 production and proliferation by blocking STAT3 activation in malignant soft tissue tumor cells. , 2006, Cancer letters.
[46] M. Meyerson,et al. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. , 2006, Cancer research.
[47] P. Heinrich,et al. Inhibition of gp130 Signaling in Breast Cancer Blocks Constitutive Activation of Stat3 and Inhibits in Vivo Malignancy , 2004, Cancer Research.
[48] D. Levy,et al. Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor , 1996, Molecular and cellular biology.
[49] J. Darnell,et al. Stat3 as an Oncogene , 1999, Cell.
[50] J. Scheller,et al. Interleukin‐6 Trans‐Signalling in Chronic Inflammation and Cancer , 2006, Scandinavian journal of immunology.
[51] T. Patel,et al. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. , 2006, Cancer research.
[52] W. Hahn,et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. , 2001, Genes & development.
[53] N. Hanna,et al. EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .
[54] C. Van Waes,et al. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas , 2006, Molecular Cancer Therapeutics.
[55] J. Minna,et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. , 2006, Cancer research.
[56] J. Jett,et al. Screening for lung cancer: current status and future directions: Thomas A. Neff lecture. , 2004, Chest.
[57] T. Hirano,et al. Molecular basis of the cell specificity of cytokine action. , 2002, Biochimica et biophysica acta.
[58] Hua Yu,et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells , 2001, Oncogene.
[59] W. Farrar,et al. Co-operative functions between nuclear factors NFkappaB and CCAT/enhancer-binding protein-beta (C/EBP-beta) regulate the IL-6 promoter in autocrine human prostate cancer cells. , 2004, The Prostate.
[60] Huqun,et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. , 2005, Cancer research.
[61] Kyucheol Cho,et al. Transforming growth factor-β1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-κB, JNK, and Ras signaling pathways , 2003, Oncogene.
[62] R. Jove,et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. , 2006, Cancer research.
[63] T. Mukohara,et al. Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). , 2003, Lung cancer.